NLS Biotech article

NLS asked Dr. Maya Fuerstenau-Sharp, Head of Marketing, Cell Culture Technologies, Bioprocess Solutions, at Sartorius about her experiences of mRNA development and manufacturing, and her view on the field and its potential.

The expanded funding will be used to further optimize the development of production processes that enable faster antigen production, as well as to conduct additional preclinical studies with Abera’s vaccine platform and vaccine candidates.

Oncopeptides has announced the publication of new real-world data (RWD) that further support the effectiveness and tolerability of melflufen, branded in Europe as Pepaxti, in patients with relapsed, refractory multiple myeloma (RRMM).

Understanding the science is one thing, but being able to manufacture T-cell therapies at scale is a different matter. TCR-T cell therapies offer a path forward at a fraction of the cost and time of manufacturing a living cell as a product. 

CSL Behring Denmark has announced that the first Danish patients with haemophilia B were treated with the gene therapy HEMGENIX (etranacogene dezaparvovec).

Anocca has announced the submission of its first Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for a Phase I/II multi-asset umbrella trial, VIDAR-1.